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Abstract
Parkinson’s disease is a neurodegenerative condition involving the death of dopaminergic
neurons in the substantia nigra. Dopamine D1 receptor agonists are potential alternative
treatments to current therapies that employ L-DOPA, a dopamine precursor. We evaluated the
pharmacological profiles of the enantiomers of a novel dopamine D1 receptor full agonist,
doxanthrine (DOX) at D1 and α2C adrenergic receptors. (+)-DOX displayed greater potency and
intrinsic activity than (-)-DOX in porcine striatal tissue and in a heterologous D1 receptor
expression system. Studies in MCF7 cells, which express an endogenous human dopamine D1like receptor, revealed that (-)-DOX was a weak partial agonist/antagonist that reduced the
functional activity of (+)-DOX and dopamine. Surprisingly, (-)-DOX had 10-fold greater
potency than (+)-DOX at α2C adrenergic receptors, with an EC50 value of 4 nM. These findings
demonstrate a reversed stereoselectivity for the enantiomers of DOX at D1 and α2C receptors and
have implications for the therapeutic utility of doxanthrine.
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1. Introduction
Parkinson’s disease (PD) is a neurodegenerative condition that involves the selective
degeneration of dopaminergic neurons in the substantia nigra, resulting in a dopamine deficiency
in the basal ganglia, a brain area that is essential for initiation and control of voluntary
movement. The degeneration of the nigrostriatal pathway leads to the classic symptoms of PD,
including tremors, rigidity, and slowness of movement (Dawson and Dawson, 2003). The most
widely-used treatment for PD is levodopa (L-DOPA), a dopamine precursor that crosses the
blood brain barrier and is enzymatically converted into dopamine (Hurley and Jenner, 2006).
Although L-DOPA is currently the “gold standard” for PD treatment, it produces both acute and
long-term adverse effects and loses its efficacy in late stage PD.
Additional PD therapies include dopamine agonists that directly stimulate dopamine
receptors in the striatum. The dopamine receptors are classified into two families. The dopamine
D1 receptor family, comprised of the D1 and D5 receptors, stimulates adenylate cyclases through
coupling with the stimulatory G proteins Gαs and Gαolf (Huang et al., 2001). The dopamine D2like receptor family (D2, D3, and D4 receptors) couples with inhibitory G proteins Gαi/o, leading
to inhibition of adenylate cyclase or modulation of other effectors (Neve et al., 2004). Currently
available direct agonists for PD target the D2-like receptors and include bromocriptine,
ropinirole, and pramipexole (Hurley and Jenner, 2006; Schapira et al., 2006). Dopamine D2
agonists appear primarily effective in early stage PD and as adjuncts to L-DOPA. Similar to LDOPA, D2-like receptor agonists have been shown to produce dyskinesias (Jenner, 2003;
Olanow et al., 2004).
Alternative pharmacological treatments under development for treating PD have included
selective dopamine D1 receptor agonists (for review see Zhang et al, 2008). Dihydrexidine
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(DHX) was the first selective, full dopamine D1 receptor agonist, and displays moderate 10-fold
selectivity for dopamine D1 versus dopamine D2 receptors (Brewster et al., 1990; Mottola et al.,
1992). Taylor et al. (1991) first demonstrated that DHX was remarkably effective at reducing
MPTP-induced Parkinson-like symptoms in monkeys. Additionally, in a small human patient
trial ABT431, another selective D1 agonist, was demonstrated to be as efficacious as L-DOPA at
alleviating the symptoms of PD (Rascol et al., 2001). These studies confirmed, contrary to
conventional wisdom, the importance of the dopamine D1 receptor as a potential target for PD.
We recently described the synthesis and preliminary characterization of doxanthrine
(DOX), a bioisostere of DHX that has improved selectivity for dopamine D1 receptors (Cueva et
al., 2006). Racemic DOX displayed approximately 100-fold greater selectivity for D1 over D2
receptors (Cueva et al., 2006). We found that (+)-DOX displayed 200-fold selectivity for D1 over
D2, whereas (-)-DOX possessed only 20-fold selectivity for D1 versus D2 receptors. These
studies revealed that (+)-DOX is a potent full agonist at the recombinant human D1 dopamine
receptor. Here we have extended our studies to examine the functional activity of both the (+)
and (-) enantiomers of DOX using porcine D1-like receptors as well as a novel endogenous
human D1-like dopamine receptor model. To validate our biochemical studies, we used an in
vivo mouse model to investigate the biological activity of both the (+) and (-) enantiomers of
DOX to produce changes in locomotor activity.
In addition, the initial study by the NIMH-sponsored Psychoactive Drug Screening
Program revealed that racemic DOX possesses significant binding affinity for the α2C adrenergic
receptor (Cueva et al., 2006). In view of the fact that α2 adrenergic receptors are responsible for
control of blood pressure, blood flow, and neurotransmitter release (Brede et al., 2004; Docherty,
1998), it seemed likely that racemic DOX might have additional undesirable pharmacological
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targets. Thus, we also examined the functional properties of (±)-, (+)-, and (-)-DOX at the α2C
adrenergic receptor using a recombinant heterologous system.
In this work we demonstrate that (+)-DOX is a potent dopamine D1 receptor agonist in
several systems. By contrast, (-)-DOX is a weak partial agonist at D1 receptors, but exhibits
potent agonist activity at α2C receptors. Thus, enantioselectivity for activity at the α2C receptor is
reversed compared to the D1-like (and D2-like) receptors (Cueva et al., 2006). This finding is
remarkable in view of the fact that the D1, D2, and 2 receptors are all Family A G proteincoupled receptors, presumably with a common rhodopsin-like structure, and has theoretical
relevance to understanding the binding motifs of agonist ligands in these receptors. Of more
practical significance, however, is the demonstration that (+)-DOX has clear superiority over
racemic DOX as a potential therapeutic agent, where the off-target α2C adrenergic receptor
activation of (-)-DOX in the racemate would produce unwanted side effects. This interesting
example is illustrative of a case where the less active enantiomer in a racemate is not simply
inert, or “less active,” but possesses an active pharmacology that diverges from that of its
antipode.

2. Materials and Methods
2.1. Chemicals and Reagents
[3H] Cyclic AMP (30 Ci/mmol) was purchased from PerkinElmer (Boston, MA, USA).
Dopamine, clonidine, SCH-23390, SKF38393, and isobutylmethylxanthine were purchased from
Sigma-Aldrich Chemical Company (St. Louis, MO, USA). Forskolin was purchased from Tocris
Bioscience (San Diego, CA, USA). Enantiomers of DOX were synthesized as described
previously (Cueva et al. 2006). pcDNA3.1/V5/his TOPO human D1 dopamine receptor was a gift
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from Dr. Bryan Roth and pcDNA3.1-α2C was provided by Missouri S&T cDNA Resource Center
(www.cdna.org).
2.2. Production of Cell Lines
HEK-α2C cells were constructed by stable transfection of HEK 293 cells with pcDNA3.1(+)-α2C. G418 resistant clones were selected and assayed for α2C function by measuring
clonidine-mediated inhibition of forskolin-stimulated cyclic AMP accumulation. HEK-CreLuc
cells were constructed by stable transfection of HEK 293 cells with pGL3, which contains the
luciferase (Luc) gene under the transcriptional control of five copies of the cyclic AMP response
element (CRE). HEK-D1 cells were constructed by stable transfection of HEK-CreLuc cells with
pcDNA3 V5 HisTopo-hD1. Clones were assayed for D1 receptor binding using [3H] SCH23390
and for function by measuring dopamine-stimulated luciferase activity.
2.3. Cell Culture
HEK-α2C cells were maintained in DMEM with 5% Fetalclone I, 5% bovine calf serum,
0.05 μg/ml penicillin, 50 μg/ml streptomycin, 25 μg/ml amphotericin B, and 300 μg/ml G418.
MCF7 cells were maintained in MEM with 10% Fetalclone III, 1.0 mM sodium pyruvate, 0.01
mg/ml insulin, 0.05 μg/ml penicillin, 50 μg/ml streptomycin, and 25 μg/ml amphotericin B
(Pitfield et al., 2006). HEK-D1 cells were maintained in DMEM with 5% Fetalclone I, 5%
bovine calf serum, 0.05 μg/ml penicillin, 50 μg/ml streptomycin, 25 μg/ml amphotericin B, 300
μg/ml G418, and 2 μg/ml puromycin. Cells were grown at 37 °C in a humidified incubator with
5% CO2.
2.4. Cyclic AMP accumulation assay
Assays were performed on confluent monolayers of cells in 48-well plates. All drugs
were diluted in Earle’s balanced salt solution (EBSS) assay buffer (EBSS containing 2% bovine
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calf serum, 0.025% ascorbic acid, and 15 mM HEPES, pH 7.4) and added on ice. Cyclic AMP
accumulation assays were performed by incubating the cells with ligands for 15 minutes at 37 C.
Assays were performed on HEK-α2C cells in the presence 30 μM forskolin (to stimulate cyclic
AMP accumulation) and 1 μM SCH23390 to preclude activation of low levels of endogenous
D1-like dopamine receptors. All assays were performed in the presence of 500 μM isobutylmethylxanthine (IBMX) and terminated with ice-cold 3% trichloroacetic acid.
2.5. Cyclic AMP binding assay
Cylic AMP accumulation was quantified using a previously described protocol (Watts
and Neve, 1996). Briefly, trichloroacetic acid extracts (10-20 μL) were added in duplicate to
cyclic AMP binding buffer (100 mM Tris-HCl, pH 7.4, 100 mM NaCl, 5 mM EDTA) in assay
tubes containing 1 nM [3H] cyclic AMP (final concentration) and bovine adrenal gland cyclic
AMP binding protein (100-150 μg in 500 μl binding buffer). The binding assay was incubated on
ice at 4 °C for 2-4 h and terminated by harvesting with ice cold wash buffer (10 mM Tris, 0.9%
NaCl) using a 96-well Packard Filtermate cell harvester and Multiscreen Harvest Plates from
Millipore (Billerica, MA, USA). Packard Microscint O (40 μL) was added to each well after
drying. Radioactivity was counted using a Packard Topcount scintillation counter. Standard
curves ranging from 0.01 to 300 pmol of cyclic AMP were used to determine the concentration
of cyclic AMP in each sample. Data analysis was performed using GraphPad Prism software.
Dose response curves for cyclic AMP accumulation were analyzed using nonlinear regression
and data were fit to a sigmoidal dose-response curve (slope = 1) to provide estimates for EC50
and intrinsic activity values.
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2.6. Porcine Striatal Adenylate Cyclase Assay
Fresh porcine brain tissue was provided by the Purdue Butcher Block. Striatal tissue was
isolated by dissection and suspended in nine volumes of homogenization buffer (20 mM Hepes,
0.32 M sucrose, pH 7.4), followed by homogenization using 10-15 strokes with a WheatonTeflon glass homogenizer. The resulting mixture was centrifuged at 1,000 x g for 10 min at 4 °C.
The pellet was washed in 10 mL of homogenization buffer and centrifuged again at 1,000 x g for
10 min at 4 °C. The resulting supernatants were combined and centrifuged at 30,000 x g for 10
min at 4 °C. The pellet was resuspended in 20-100 mL of 50 mM Tris buffer (pH 7.4) by briefly
using a Kinematica homogenizer and was centrifuged at 30,000 x g for 30 min at 4 °C. This
pellet was resuspended again in 50 mM Tris buffer, dispensed into 1 mL aliquots, and
centrifuged for 10 min at 13,000 x g and 4 °C. A BCA protein assay was used to determine the
final protein concentration of the pellets. The supernatant was aspirated and the pellets were
frozen at -80 C until use.
The striatal adenylate cyclase assay protocol was adapted from previously published
methods (Chester et al., 2006). Assays were carried out in 96-well assay tubes containing (final
concentration) reaction buffer (5 mM MgCl2, 2 mM EDTA, 1 mM IBMX, 0.01% ascorbic acid,
10 μM pargyline, and 15 mM HEPES, pH 7.4), 20 μL reaction mix (1.25 mM adenosine 5’triphosphate (ATP), 21.5 mM N-[imino(phosphonoamino)methyl]-N-methylglycine disodium
salt (phosphocreatine), and 3 U creatine phosphokinase), 1 μM Gpp(NH)p, 30 μg striatal protein,
and the indicated drugs, all in a total volume of 100 μL. Duplicate samples for each treatment
were incubated in a 30 °C water bath for 15 min. Adenylate cyclase activity was terminated by
the addition of 200 μL of 3% trichloroacetic acid. The reaction tubes were covered with parafilm
and stored at 4°C until the concentration of cyclic AMP was quantified as described above.
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2.7. Mouse Locomotor Activity
Drug naïve male Swiss-Webster mice (Harlan, Indianapolis, IN) were housed in groups
of 3-5 with free access to food and water under a 12/12 h light/dark cycle (lights on at 0700). All
mice weighed between 25 and 35 grams and were approximately 8-9 weeks of age at the start of
the experiment. Experimental procedures were conducted between 0800 and 1200.
Locomotor activity was monitored using an open field activity frame (SmartFrame Low
Density, Lafayette Instrument Co, Lafayette, IN) that contained eight infrared photo beams along
the long axis and four along the short axis of each frame [internal frame dimensions: 24.13 x
45.72 centimeters (cm)]. The frames surrounded a Plexiglas chamber that resided on top of
black polyurethane enamel coated metal trays. Hamilton-Kinder MotorMonitor (Model
HMM100) software was used to monitor activity.
Mice were randomly assigned to one of five treatment groups: vehicle/vehicle (n=8);
vehicle/(-)-DOX (n=8); vehicle/(+)-DOX (n=8); SCH23390/(+)-DOX (n=8); SCH23390/vehicle
(n=6). For activity testing, individual mice were weighed and placed in the locomotor activity
chambers for 30 minutes to acclimate them to the testing environment. Mice were then removed
from the chamber and injected with either 0.03 mg/kg SCH23390 or vehicle. After a 20 min
pretreatment time, mice were subsequently injected with either 5.0 mg/kg (+)-DOX, 5.0 mg/kg
(-)-DOX, or vehicle, and placed into the locomotor activity chambers for 60 min. All drugs were
dissolved in physiological saline with 0.02% ascorbic acid to prevent drug oxidation and were
injected intraperitoneally in a volume of 10 mL/kg body weight. Activity data were collected in
5-min epochs and data presented represent total distance traveled (cm) during the first 30 min of
the testing session. Data were analyzed using a one-way ANOVA followed by post-hoc Student
Newman-Keuls test using SPSS 15.0.1.1 and GraphPad Prism software.
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3. Results
3.1. (+)-DOX is a potent agonist at the dopamine D1 receptor
We initially compared stimulation of cyclic AMP accumulation by the enantiomers of
DOX using a heterologous expression system of HEK cells that stably express the human
dopamine D1 receptor. Consistent with our previous studies (Cueva et al., 2006), both
enantiomers stimulated cyclic AMP accumulation in this system. The (+) enantiomer of DOX
displayed full intrinsic activity (111 ± 3 %) relative to dopamine with an EC50 of ca. 50 nM
(Figure 1). The (-) enantiomer of DOX displayed markedly reduced potency with a moderate
reduction in intrinsic activity when compared to either (+)-DOX or dopamine (Figure 1).
Knowledge that the functional activity of D1 receptor agonists can be distorted in the
presence of spare receptors in heterologous systems (Watts et al., 1995) prompted additional
experiments in cells expressing an endogenous human D1-like dopamine receptor. For these
experiments we took advantage of cell growth studies implicating the presence of a D1-like
receptor in the MCF7 human breast cancer tumor cell line (Johnson et al., 1995). To initiate
these studies, we completed a characterization of the human dopamine D1-like receptor using the
well-studied full D1 receptor agonist DHX and the partial D1 receptor agonist, SKF38393. These
experiments revealed that dopamine, DHX, and SKF38393 stimulated cyclic AMP accumulation
in a dose-dependent manner in MCF7 cells, with EC50 values of 1120 ± 100 nM, 81 ± 1 nM, and
1060 ± 290 nM, respectively (n = 3). DHX was a “full” agonist relative to dopamine, whereas
the selective partial agonist, SKF38393 displayed the anticipated reduced intrinsic activity (ca.
30% relative to dopamine) (Figure 2A). The intrinsic activities of DHX and SKF38393 in MCF7
cells studies are consistent with previous studies using human striatal tissue (Gilmore et al.,
1995). To characterize this cell model further, we carried out antagonist studies using the
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dopamine D1 antagonist, SCH23390 (Figure 2B). Incubation with SCH23390 resulted in a
complete blockade of agonist-stimulated cyclic AMP accumulation, indicating the presence of a
functional human dopamine D1-like receptor in MCF7 cells.
Having established MCF7 cells as a model for assessing D1 agonist activity, the
functional properties of the enantiomers of DOX were then evaluated. Studies with racemic (±)DOX revealed that it was more potent than dopamine; however, the intrinsic activity appeared to
be slightly reduced compared to dopamine (Figure 3A). In results that were consistent with
those from the heterologous expression system, (+)-DOX displayed intrinsic activity that
appeared to be greater than that of dopamine, suggesting that (+)-DOX may have greater efficacy
than dopamine itself. In contrast, (-)-DOX had only 30% intrinsic activity when compared to
dopamine. This finding suggests that (-)-DOX is a partial agonist and would have antagonist
activity at dopamine D1 receptors (Figure 3A). Thus, we evaluated the ability of (-)-DOX to
antagonize dopamine- and (+)-DOX-stimulated cyclic AMP accumulation in MCF7 cells by
measuring dose-response curves in the absence or presence of 10 μM (-)-DOX. As anticipated,
the addition of 10 μM (-)-DOX reduced the intrinsic activity and potency of both dopamine and
(+)-DOX (Fig. 3B,C). The (-)-DOX-induced reduction in the intrinsic activity of (+)-DOX
indicates that (-)-DOX contributes significant antagonist activity within racemic DOX, consistent
with the results shown in Figure 3A. Curiously, as shown in figures 3B,C, increasing
concentrations of either dopamine or (+)-DOX failed to overcome the attenuated cAMP response
produced by (-)-DOX. These results suggest that (-)-DOX may be acting either as a
noncompetitive antagonist, or perhaps as a negative allosteric modulator of the D1 receptor.
In the absence of human striatal tissues to study a native D1-like dopamine receptor, (+)DOX was evaluated and compared to dopamine and SKF383983 at D1-like dopamine receptors
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in porcine striatal tissue. This series of functional studies revealed that (+)-DOX had high
intrinsic activity (115 ± 15%; n = 3) and an EC50 of 68 ± 14 nM; n = 3 (Figure 4). Consistent
with results obtained using the heterologous expression system and MCF7 cells, (+)-DOX also
was more potent than dopamine, which had an EC50 value of 370 ± 77 nM (n = 3) in porcine
striatal tissue.
3.2. (-)-DOX is a potent agonist at the α2C adrenergic receptor
The NIMH-sponsored Psychoactive Drug Screening Program assessed racemic DOX and
reported that it possessed significant affinity for α2 adrenergic receptors (Cueva et al., 2006).
The estimated Ki values for α2A, α2B, and α2C receptors were 180, 10, and 2 nM, respectively. In
light of these observations, we evaluated the functional activity of the enantiomers of DOX at the
α2C adrenergic receptor. A heterologous expression system in which HEK293 cells stably
expressed the α2C receptor was constructed to examine the ability of (+)- and (-)-DOX to inhibit
forskolin-stimulated cyclic AMP accumulation. The prototypical α2 agonist clonidine was used
for comparison. Surprisingly, (-)-DOX had an EC50 value of 4.4 ± 2.3 nM (n = 3) in these cells,
was nearly four-fold more potent than clonidine (EC50 = 17 ± 3.2 nM, n = 3), and was 30-fold
more potent than (+)-DOX (EC50 = 151 ± 25 nM, n = 3) (Figure 5). Perhaps more striking is the
marked intrinsic activity difference between the two enantiomers of DOX at the α2C receptor.
(-)-DOX exhibited intrinsic activity similar to that of clonidine, whereas (+)-DOX had very low
intrinsic activity (34 ± 7% inhibition) that was only ca. 50% of that displayed by (-)-DOX.
Moreover, the addition of a selective α2 antagonist, rauwolscine (10 µM) antagonized the (-)DOX- and clonidine-mediated inhibition of forskolin stimulation of cyclic AMP, demonstrating
that this effect was specific for the activation of the α2C receptor (data not shown). These results
clearly show that the data from the NIMH-sponsored affinity studies of α2C adrenergic receptors
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with racemic DOX primarily reflect the binding of (-)-DOX. Additionally, we reveal for the first
time that the stereoselectivity of the enantiomers of the rigid D1 agonist DOX is reversed
between dopamine D1 and α2C adrenergic receptors.
3.3. (+)-DOX and (-)-DOX produce opposite effects on locomotor activity
When administered alone, (+) and (-)-DOX produced opposite effects on locomotor
activity (Figure 6). One-way ANOVA of total distance traveled during the first 30 min revealed
a significant difference between treatment groups (F4,33 = 7.0, p < 0.001). Student NewmanKeuls post-hoc analysis indicated that (-)-DOX decreased distance traveled compared to the
vehicle group (p < 0.05), whereas (+)-DOX increased distance traveled compared to the vehicle
group (p < 0.05). Pretreatment with the D1- selective antagonist, SCH23390 (0.03 mg/kg, i.p.,
20 min pretreatment) blocked the locomotor-stimulatory effects of (+)-DOX. SCH23390
administered alone did not alter locomotor activity when compared to the vehicle group (Figure
6).
4. Discussion
DOX is a recently synthesized analogue of DHX, a full dopamine D1 agonist with antiparkinsonian activity in MPTP-treated non human primates (Cueva et al., 2006; Taylor et al.,
1991). In the present studies, we have examined the pharmacological properties of the
enantiomers of DOX at dopamine D1 and α2C adrenergic receptors. Initial experiments compared
the functional activity of (+)-DOX and (-)-DOX, as well as the endogenous agonist dopamine, at
the D1 dopamine receptor using a heterologous D1 expression system (HEK-D1 cells), a novel
cell model system that endogenously expresses a D1-like receptor (MCF7 cells), and porcine
striatal tissue. The (+) enantiomer of DOX displayed full agonist properties and was more potent
than dopamine and (-)-DOX in all three systems. The ability of (+)-DOX to increase locomotor
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activity also is consistent with a D1-like activation profile (Desai et al., 2005). It should be
noted, however, that the effects of (+)-DOX on locomotor activity in the present study are quite
modest when compared to the robust increase observed in response to amphetamine (Villarreal et
al., 1973).
In contrast, functional studies using the α2C adrenergic receptor revealed that (-)-DOX
was more potent than (+)-DOX. Furthermore, (-)-DOX also was four-fold more potent than
clonidine at activating α2C adrenergic receptors. Consistent with these results, (-)-DOX produced
a reliable decrease in locomotor activity in mice within the first 30 minutes of administration
(Figure 6). This result is consistent with studies using other 2 agonists such as clonidine, which
produce distinct suppression of locomotor activity in rodents (Capasso and Loizzo, 2001).
This reversal of stereoselectivity has implications for the use of DOX as a potential
therapeutic agent. For example, administration of (+)-DOX, as opposed to the racemic mixture,
would allow for full stimulation of the dopamine D1-like dopamine receptor in the absence of
potentially significant adverse side effects associated with activation of the α2C receptor. In
addition to possessing disparate pharmacology, the two enantiomers may have different
pharmacokinetic and pharmacodynamic properties due to stereoselective interaction with other
molecular targets (Waldeck, 2003).
Fundamentally, the development of a single enantiomeric form of a drug is to minimize
the xenobiotic load on the organism by reducing the levels of foreign molecules not normally
present (Ariens, 1990). The development of therapeutic agents that are enantiomerically pure
also will minimize the potential for off target effects by the “inactive” enantiomer. For example,
one isomer of the drug may possess a desirable physiological and pharmacological response,
whereas the other potentially could produce adverse effects by activation of other biological
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targets or enzymes. This situation is not what is typically observed but is, however, the result
observed in our studies with the enantiomers of DOX.
Common examples of enantiomeric drugs include (S)-citalopram (Escitalopram or
Cipralex™), a member of the SSRI antidepressant family (Izake, 2007). Escitalopram is a
selective serotonin reuptake inhibitor in which the S enantiomer is 150 times more potent than
the R enantiomer as a serotonin transporter inhibitor (Hyttel et al., 1992). Another example of a
single enantiomer drug is Lunesta™ (Eszopiclone, or (S)-zopiclone), a nonbenzodiazepine
hypnotic agent used to treat insomnia. Although the mechanism of action of Eszopiclone is not
well understood, the S enantiomer has higher affinity and is more active at GABA receptors
(Blaschke, 1993). Thus, in a study where the behavioral effects of the enantiomers of zopiclone
were evaluated in rats, both (S)- and racemic zopiclone reduced locomotor activity, whereas (R)zopiclone did not, showing that the sedative effects are mediated solely by the S enantiomer
(Carlson et al., 2001). In neither of these examples, however, was there any evidence that the
enantiomer with lower potency for the desirable therapeutic response produced any adverse
effects.
By contrast, in this study we have shown that (-)-DOX, which has lower potency and
intrinsic activity as an agonist at the D1 dopamine receptor, actually is a potent agonist with high
intrinsic activity at 2C-adrenergic receptors, with potential adverse actions such as sedation and
effects on blood pressure resulting from 2 receptor activation. Further, the indication that (-)DOX may be a noncompetitive antagonist or negative allosteric modulator of the D1 receptor
suggests that the combination of enantiomers, in the form of the racemate, would be detrimental
to therapeutic efficacy. In essence, one could consider the enantiomers of DOX to be completely
different pharmacological entities.
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PD patients experience significant relief in response to initiation of L-DOPA drug
therapy. The onset of dyskinesias, however, an impairment of voluntary movement, is a side
effect that commonly develops upon long-term treatment with L-DOPA. Moreover, the
effectiveness of L-DOPA eventually declines as the disease progresses (Olanow et al., 2004).
Clinically available alternatives to L-DOPA are based on the hypothesis that the therapeutic
effects of L-DOPA are mediated through dopamine D2-like receptors. Despite that belief,
however, D2 dopamine agonist monotherapy is not as efficacious as L-DOPA at alleviating PDlike symptoms. The lack of D2 agonist efficacy as a monotherapy when compared with L-DOPA
indirectly supports the role of D1-like receptors in PD therapy. More direct evidence, however,
is the demonstration that the selective D1 agonists DHX, ABT 431, and CY208-243 reduced PDlike symptoms in a non-human primate model (Taylor et al., 1991; Temlett et al. 1988), as well
as PD symptoms in humans (Rascol et al., 2001; Tsui et al., 1989), with efficacy comparable to
L-DOPA, thereby demonstrating the importance of D1 receptors as targets for the therapy of PD.
Dopamine agonists may have additional therapeutic roles beyond the relief of PD
symptoms, including neuroprotective effects that lead to neuronal survival (Lewis et al., 2006).
The partial D1 dopamine agonist SKF38393 reduces aspects of MPTP-neurotoxicity
(Muralikrishnan and Ebadi, 2001) and protects against malonate-induced lesions (Fancellu et al.,
2003). Additionally, dopamine treatment resulted in a reduction of apoptosis in cells expressing
both D1 and D2-like receptors (Colombo et al., 2003). This effect was blocked by the D1selective antagonist, SCH23390, but not by the D2-selective antagonists haloperidol or
domperidone, thereby suggesting that activation of D1-like receptors is anti-apoptotic.
Dopaminergic neuronal degeneration and the subsequent dopamine deficit can result in a
characteristic impairment of cognition and working memory in individuals with PD (Castner and
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Goldman-Rakic, 2004). Stimulation of the D1 receptor enhances working memory in humans,
dopamine-deficient monkeys, and aged monkeys (Arnsten et al., 1994; Cai and Arnsten, 1997;
Castner and Goldman-Rakic, 2004; Davidson et al., 1990; Schneider et al., 1994). Monkeys
exposed to low doses of MPTP, a neurotoxin that targets and results in the death of dopaminergic
neurons, develop severe cognitive dysfunction. Administration of DHX resulted in a dosedependent improvement of working memory and this effect was blocked by the D1 receptor
antagonist SCH-23390 (Schneider et al., 1994). Dopaminergic deficits also can occur during the
natural aging process, resulting in impairment of short and long term memory. Castner and
Goldman-Rakic (2004) demonstrated that aged rhesus monkeys (20-30+ years of age) displayed
a significant improvement in working memory task performance following administration of the
D1 receptor agonist ABT-431. In addition, this enhancement in cognitive function persisted for
more than one year after ABT-431 administration, suggesting that stimulation of D1 receptors
may induce long-term alterations in the neurocircuitry of working memory. Most recently, a
clinical trial of DHX in schizophrenia has shown that a single dose can significantly enhance
blood flow to the prefrontal cortex, a brain area implicated in working memory (Mu et al., 2007).
Unfortunately, the clinical application of D1 agonists (e.g. DHX) generally has been hampered
by low bioavailability. Very recently, however, in vivo studies in our laboratory using the 6-OHDA lesioned “rotating rat” model have provided data suggesting that DOX has significant oral
bioavailability (McCorvy et al., unpublished observations).
In conclusion, the present study has demonstrated that (+)-DOX is a potent full D1
dopamine receptor agonist that has high selectivity for D1-like dopamine receptors. In contrast,
(-)-DOX is a weak partial D1 agonist with potential D1 antagonist properties, also having
significant affinity and potency at α2C adrenergic receptors. Based on these results, we propose
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that the (+) enantiomer of DOX is an improved tool for the continued study of D1 dopamine
receptor function in vivo. Additionally, such a selective compound offers potential for
examining the role of D1-like receptors in the therapy of Parkinson’s disease, neuroprotection,
and cognitive impairment.
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Figure Legends
Figure 1. Dose-response curves for dopamine D1 receptor-mediated stimulation of cyclic
AMP accumulation. HEK-D1 cells were incubated with increasing concentrations of dopamine,
(+)-DOX, or (-)-DOX for 15 min at 37 °C. The data presented have been normalized to the
maximal cyclic AMP accumulation observed in the presence of dopamine. Data shown are the
mean ± SEM of six independent experiments assayed in duplicate.

Figure 2. Characterization of a human D1-like dopamine receptor in MCF7 cells. A. MCF7
cells were incubated with increasing concentrations of dopamine, DHX, or SKF38393 for 15 min
at 37 °C. The data presented have been normalized to the maximal cyclic AMP accumulation
observed in the presence of dopamine and are the mean  SEM of three or four independent
experiments assayed in duplicate. B. Cyclic AMP accumulation under basal conditions or
following incubation with 3 µM forsklin (FSK), 5 µM dopamine (DA), 5 µM DHX, or 5 µM
SKF38393 (SKF) in the absence (control) or presence of the D1 dopamine receptor antagonist,
SCH23390 (5 μM). The data presented are the mean ± SEM of three independent experiments
assayed in duplicate.

Figure 3. Dose-dependent stimulation of cyclic AMP at the endogenous dopamine D1
receptor in MCF7 cells. A. MCF7 cells were incubated with increasing concentrations of
dopamine, (±)-DOX, (+)-DOX, or (-)-DOX for 15 min at 37 °C. The data presented have been
normalized to the maximal cyclic AMP accumulation observed in the presence of dopamine. B.,
C. Dose-response curves for dopamine- or (+)-DOX-stimulated cyclic AMP accumulation were
completed in the absence (solid symbols) or the presence of 10 μM (-)-DOX (open symbols) as
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described above. The data presented in each figure are the mean ± SEM of three independent
experiments assayed in duplicate.

Figure 4. Dose-dependent stimulation of cyclic AMP in porcine striatal homogenate.
Striatal tissue was incubated in the presence of increasing concentrations of dopamine, (+)-DOX,
or SKF38393 for 15 min at 30 °C. The data presented have been normalized to the maximal
cyclic AMP accumulation observed in the presence of dopamine and are the mean ± SEM of
three independent experiments assayed in duplicate.

Figure 5. Dose-response curves for α2C receptor-mediated inhibition of forskolinstimulated cyclic AMP accumulation. HEK-α2C cells were incubated with 30 μM forskolin in
the presence of increasing concentrations of clonidine, (+)-DOX, or (-)-DOX for 15 min at
37 °C. The data presented have been normalized to the maximal cyclic AMP accumulation
observed in the presence of forskolin alone and are the mean ± SEM of three independent
experiments assayed in duplicate. The EC50 values for (-)-DOX and clonidine in these
experiments were 4.4 ± 2.3 nM and 17 ± 3.2 nM, respectively.

Figure 6. Effects of enantiomers of DOX on locomotor activity. Swiss-Webster mice were
administered either vehicle/vehicle, vehicle/5.0 mg/kg (-)-DOX, vehicle/5.0 mg/kg (+)-DOX,
0.03 mg/kg SCH23390/5.0 mg/kg (+)-DOX, or 0.03 mg/kg SCH23390/vehicle. Data depicted
are total distance traveled (cm) during the first 30 min of the test session. Student-NewmanKeuls post-hoc analysis: * p < 0.05 compared to vehicle/vehicle group.
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